Array ( [0] => 29449 [1] => 29444 [2] => 28060 ) Array ( [0] => 29449 [1] => 29444 [2] => 28060 ) Array ( [0] => 30502 [1] => 29044 ) Array ( [0] => 30502 [1] => 29044 )

Last Updated: 19/06/2024

Impact of elminths on immunogenicity of the RTS,S malaria vaccine in children

Objectives

To characterize children’s immune responses to the new malaria vaccine to determine the impact of any accompanying infections.

Principal Institution

Kenya Medical Research Institute (KEMRI), Kenya

Principal Investigators / Focal Persons

Simon Kariuki

Rationale and Abstract

The WHO recently approved a new malaria vaccine that will mainly be deployed in sub-Saharan Africa. During its development, HIV-infected children were found to mount weaker immune responses. Helminth infections, which are prevalent in sub-Saharan Africa, are also suspected to negatively impact vaccine efficacy. To test this, they will use an antibody-dynamics platform to assess the impact of helminths and other current or prior parasitic, bacterial, and viral infections on humoral and cellular immune responses following the 4th dose of the new malaria vaccine in two- to three-year-old children at six hospitals in western Kenya. This will help design more effective deployment strategies such as deworming before vaccination.

External reference

Project details BMGF details

Thematic Categories

Vaccines (Immune Correlates)

Date

Nov 2023 — Jun 2024

Total Project Funding

$249,947

Funding Details

Bill & Melinda Gates Foundation (BMGF), United States

Grand Challenges. Supporting Researchers Through the Technologies of the Global Health Discovery Collaboratory Platforms

Grant ID: inv-060681